Alembic Pharma Q3 Review - Domestic Formulation/Non-U.S./API Segment Drive Earnings: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Alembic Pharmaceuticals Ltd. missed Q3 FY21 earnings, weighed by lower-than-expected sales in the U.S.
The adverse impact of lower price of Sartans in the U.S. was offset, to some extent, by a) healthy sales growth in the Domestic Formulation/Non-U.S./API segment and b) stable other operating expenses.
Physical inspections by the U.S. Food and Drug Administration across sites for the industry in India are delayed due to restrictions on international travel.
However, Alembic Pharmaceuticals may face the inspection earlier (over the next 3–6M) as it has filed for products on the shortage list.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.